A new adjustable single-incision bladder sling placed via the transobturator route for women with stress urinary incontinence shows promise.
An adjustable single-incision sling for treating urinary incontinence was less painful postoperatively than the standard synthetic midurethral sling placed via the transobturator route (TVT-O), according to recently published results of a randomized trial.
The study, conducted in The Netherlands, was an early assessment of a new transobturator device called Ajust, which does not require penetration of the external obturator and adductor muscles of the upper leg for proper placement. The new sling is being compared with the standard TVT-O, in the hopes of reducing postoperative pain while maintaining results.
- A new adjustable single-incision sling device for treating urinary incontinence proved to have lower postoperative pain scores when compared with the standard TVT-O, a recent study found.
The single-blinded, controlled study allocated 156 women with stress urinary incontinence to receive either an adjustable single incision using Ajust or TVT-O. Those who received the Ajust sling reported lower early postoperative pain scores using a visual analog scale, according the published results in Obstetrics & Gynecology.
In the first week postoperatively, the mean pain score was significantly lower at all time points for women in the adjustable single-incision sling group compared with the TVT-O group. However, there was no statistical difference in the use of pain medication, the authors reported.
The study also compared cure rates for both procedures, finding them to be comparable (90.8% for the adjustable single-incision sling vs 88.6% for the transobturator sling). There were no differences in complication rates for either device.
Because placing a synthetic midurethral sling using the transobturator approach is associated with more groin pain than the retropubic TVT approach, the new device aims to reduce pain associated with the procedure, according to information filed with the Netherlands Trial Register. The primary benefit of the transobturator approach, compared with the retropubic approach, is that the risk of bladder perforation is minimal.
“The groin pain is most likely due to perforation of the external obturator and adductor muscles of the upper leg,” the trial information explains. “The new transobturator device Ajust does not penetrate these muscles and is therefore in theory less painful as compared to the TVT-O, with the benefit of reducing the risk of bladder perforation as compared to the retropubic TVT.”
The trial looked at data on postoperative pain for up to six weeks after the procedure and involved weekly telephone interviews with patients.
Rising endometriosis rates linked to increased pregnancy complications
May 19th 2024A new study presented at the 2024 ACOG meeting reveals a significant rise in endometriosis among pregnant women over the past 20 years, linking the condition to increased obstetric and neonatal complications.
Read More
PCOS and irregular cycles tied to cardiometabolic risks
May 15th 2024A comprehensive analysis reveals strong associations between polycystic ovary syndrome, irregular menstrual cycles, and increased risks of cardiometabolic conditions, underscoring the importance of proactive screening and intervention strategies.
Read More
Pioglitazone outperforms metformin in IVF for PCOS-related infertility
May 6th 2024A recent double-blind, randomized clinical trial revealed a higher clinical pregnancy rate with pioglitazone compared to metformin in polycystic ovarian syndrome patients undergoing in vitro fertilization, suggesting potential for improved outcomes.
Read More